Powered by

Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD

Mar 03, 2019 - GlobeNewswire

Single dose of ensifentrine DPI formulation produced statistically significant and clinically meaningful dose-dependent bronchodilator response and was well tolerated at all doses

Data support initiation of part 2 of study to evaluate effect of ensifentrine DPI formulation over one week of treatment

First study to show efficacy of DPI formulation; Delivery via DPI could dramatically expand the clinical utility and commercial opportunity for ensifentrine in COPD and asthma